<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">481</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>INVASIVE LOBULAR BREAST CARCINOMA (ILC) IN AN ELDERLY MALE ON PROLONGED RANITIDINE THERAPY&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hiremath</surname><given-names>Srikantaiah</given-names></name></contrib><contrib contrib-type="author"><name><surname>A.</surname><given-names>Nikhil Nanjappa B.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>11</day><month>08</month><year>2015</year></pub-date><volume>)</volume><issue/><fpage>26</fpage><lpage>31</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Breast carcinoma in men is an exceedingly rare entity, contributing to 1% of all breast cancers [1], of which invasive lobular carcinoma (ILC) accounts for 1.5% [2]. The average age at diagnosis is usually five years older compared to women [1, 3]. Although the exact aetiology remains unknown, hyperestrogenic states are attributed as the most likely cause [4]. Men with family history of female breast cancer are at 2.5 times more increased risk when compared to those with no family history [5]. Lobular histologic subtype of breast carcinoma in males is rare due to the lack of acini and lobules [6]. Some medications, such as cimetidine&#13;
[7, 8] are thought to multiply the risk of male breast cancer because they induce a hyperestrogenic state. The authors report a rare case of ILC in a 75 year old man, with no known risk factors for breast cancer. However, he had a history of prolonged self-prescribed ranitidine use for dyspeptic symptoms. Although there isn__ampersandsignrsquo;t enough evidence to suggest that ranitidine, like its predecessor cimetidine, may cause male breast cancer. The authors would like to draw attention to this possibility.&#13;
</p></abstract><kwd-group><kwd>Male breast carcinoma</kwd><kwd> Male breast cancer</kwd><kwd> Invasive lobular carcinoma males</kwd><kwd> Ranitidine induced male breast cancer</kwd></kwd-group></article-meta></front></article>
